Leaders in Pharmaceutical Business Intelligence (LPBI) Group

• Will Adams, CSO, President, Founder, Riparian Pharmaceuticals – CVD drug development

1. human genetics, differential biology, therapeutics for CVD
2. Lab at HMS research on Vasculture, one important pathway
3. NIH – $500,000
4. Using CROs

• Chris Colbert, Director of Programming, Harvard Innovation Lab – seminars open to the Public

1. Harvard Entrepreneur activity for students and Alunmi, started EdTech in 2014, defining problems and solutions
2. Education vs outcomes – capacity to start a business
3. complementary to Education, resources to become entrepreneur
4. individuals are driving the process
5. AI

• Tim Wang, Co-founder, KSQ Therapeutics

1. at MIT, now with VC at KSQ, 30-40 emp, hires are computentional biology, cancer biology from pulls of Boston-based Postdocs,
2. involvement in wriitng a business plan and funding
3. being active and interdisciplinary

• Sources of inspirations Henri A. Termeer the founder of Genzyme
• Consumer of HealthCare for 62 years is critical: Trust and Access for vulnerable patient when they are ill
• Return on Investment in Drugs, incentives to develop vs generics, BioSimilars, Price will drop
• Societal contract: Recognizing the value and the Pharma Industry needs to increase self regulating
• If Gov’t will regulate PRICE of drug, innovations will decrease
• Thank you for the award

• 2100 emp in MA
• single building in Kendall Square
• Andover facility
• three R&D units: Drug Discovery

Pfizer, Accepted by Morrie Birnbaum, SVP & CSO, Internal Medicine

• 2014 – Kendall Square site: Becoming Premier Pfizer’s Research Center, close to Science, Scientists and Patients
• Recognition that working with Foundations and Academic centers Not able to do it alone
• Close relations with MassBio
• Thanks to MassBio

• Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute

1. Was part of Cancer Moonshot – 10 key directions
2. Fund $1.8 Billion, fund needs be approved each year
3. Funds for 12 implimentation Teams – Applications for 10 key directions: How a Tumor evolve and resist treatment
4. Create an initiative of Data Sharing acquired from Patients
5. understanding mutation unique
6. cancer immunotherapy: fight tumor, stimulate immune system CHeck-Point blockers – only 20% of patients are responsive
7. Big data to identify new drug targets so more patients will respond
8. Tsunami in BioMedical Research regarding NIH to face $1.2 Billion cut (equal indirect cost)  – Patients are best advocates –
9. MA figured out how to do collaboration among stackholders
10. Several Cancers will become Chronic diseases not quite Cure in 5-10 years
11. Prevention and early detection: Vaccination, HPV (only 14% girls get vaccine for Cervical, anal and throat) in Japan 0% of HPV.
12. environment that surrounding the tumor, immune cells suppressing the immune system

• Mathew Meyerson, Prof. of Pathology, Dana-Farber Cancer Institute, Broad Institute

1. 3-D cancer genomics sequencing for every cell, new therapies interaction of Cancer and the environment, computing and Internet use for Patient direct involvement in Research – enrollment
2. Child Cancers
3. Prevention: Vaccination, HPV, HEP B
4. HIV a cocktail of drugs, kill a cancer from many angles
5. access to clinical trial: Connect Clinical Trials information with Doctors
6. Electronic cigarets and Lung cancer – connection needs to be researched

• Chandra Ramanathan, Head East Coast Innovation Center, Bayer US

1. Bayer Partnership with Broad Institute
2. Immunotherapy Combination of Biomarkers
3. Sharing Data from Clinical Trials

• Seema Singh Bhan, Head, Public Policy, Foundation Medicine

1. Technology to
2. harness Big data
3. Momentum via NCI, Cancer Moonshot
4. Foundation Medicine: Collaboration: Pharma, Goventment, FDA, Academic Institution 0 Liquid Biopsy assays developed and go through the Regulatory system
5. Patient-Doctor – List of Clinical Trials available for Patients

2:30 – 3:15 Breakout Sessions

• 2:30 pm – 3:15 pm

• CRISPR and What’s Next

  Trends in Science
  2:30 pm – 3:30 pm